RET and thyroid cancer: Third, because we can only conduct WES with FFPE samples, it is impossible for us to detect the fusion genes commonly reported in thyroid cancer (e.g., CCDC6-RET and NTRK fusions) (49), which could be the driver genomic event in the primary tumor of our patient and shared by all the metastatic samples.